Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Indiana for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Indiana only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Indiana (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Michael Tallarico (NPI 1467773036)

Field	Value
Entity Type	Individual
Organization	Michael Tallarico
Address	1001 Calumet Ave
City	Dyer
State	IN
ZIP	46311
Taxonomy	Medical Oncology Physician
NPI Enumerated	June 17, 2010

Payer Source	Total Paid
Medicare	$2.7M
Medicaid	$0

Key Findings

This provider is effectively a Medicare-only billing entity: Total Medicare revenue is $2.7M and there is no Medicaid billing on file, so payer mix is heavily concentrated on Medicare reimbursements. The top three Medicare codes account for 68.4% of this provider's total Medicare revenue, indicating limited diversification across payers and a revenue base concentrated in a few therapies.

The code mix and top revenue drivers point to an outpatient oncology infusion practice focused on immunotherapy and bone-targeted therapy. The largest single revenue source is J9271 (pembrolizumab) with 27.6K claims and $1.2M revenue (47.6% of this provider's total Medicare revenue), complemented by J9022 (atezolizumab) with 4.5K claims and $287.2K revenue (11.5%) and J0897 (denosumab) with 12.8K claims and $230K revenue (9.2%), consistent with a practice that delivers high-volume biologic infusions and related supportive care.

Revenue concentration is acute: J9271 alone represents 47.6% of Medicare revenue and the precomputed top-three share is 68.4%, meaning the practice’s financial performance is highly sensitive to utilization or reimbursement changes for a very small set of drugs. Operationally this implies procurement, scheduling, and reimbursement workflows are likely engineered around repeated high-volume delivery of a few high-cost injectable therapies.

Competitive standing by code is mixed but shows above-average national presence for key oncology drugs. J9271 ranks #166 of 1841 providers nationally (91th percentile) and is labeled as "typical, unremarkable volume for this code," indicating the provider has a meaningful national-level footprint for pembrolizumab; J9022 ranks #20 of 39 (50th percentile) and is also labeled "typical, unremarkable volume for this code," suggesting middling representation for atezolizumab; J0897 ranks #732 of 10057 (93th percentile) and is labeled "typical, unremarkable volume for this code," which together show the practice is a solid but not uniquely dominant participant across these agents.

Evaluation-and-management and infusion visit codes are notable outliers relative to national peers, implying substantial face-to-face and infusion-based follow-up care. The provider reports 2K claims for 99214 totaling $174.7K (7.0% of Medicare revenue) and this code is labeled an "extreme outlier, far above typical national volume for this code," while 99213 (846 claims, $51.6K, 2.1%) is labeled "notably above typical national volume for this code," consistent with a high-volume clinic visit load supporting infusion services.

Chemotherapy administration and supportive-care utilization reinforce the infusion specialty profile: 96413 (chemotherapy administration) has 757 claims and $70.4K revenue (2.8%) and is labeled "notably above typical national volume for this code," while supportive agents such as J1449 (eflapegrastim-xnst) with $62.7K (2.5%) and Q5122 (pegfilgrastim-apgf) with $46.2K (1.9%) indicate routine use of growth-factor support and related oncology supportive treatments.

High-volume phlebotomy and laboratory monitoring activity accompanies the infusion practice, suggesting substantial on-site or closely coordinated lab services to support treatment management. Several lab codes (multiple entries with ~2.4K claims each, e.g., 85025, 84075, 84132) appear in the top-25 list; 84132 in particular is ranked in the 99th percentile and labeled "notably above typical national volume for this code," while 36415 (2.5K claims, $20K) is labeled "typical, unremarkable volume for this code," together indicating frequent routine monitoring tied to oncology care.

The provider has an established billing history with NPI enumerated 2010-06-17 (~16 years ago), which, combined with the sustained high-volume drug and visit billing profile, suggests a mature outpatient oncology operation. Given the concentration of revenue in a few high-cost biologics and heavy Medicare reliance, the practice appears operationally stable but exposed to shifts in drug utilization, formulary changes, or Medicare policy affecting those specific codes.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

80 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	27,600	$40	$1.2M
J9022	Injection, atezolizumab, 10 mg	4,490	$60	$287.2K
J0897	Injection, denosumab, 1 mg	12,780	$20	$230K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,960	$90	$174.7K
J1437	Injection, ferric derisomaltose, 10 mg	6,800	$20	$115.6K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	760	$90	$70.4K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	2,510	$30	$62.7K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	850	$60	$51.6K
Q5122	Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg	440	$100	$46.2K
99233	The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the…	420	$90	$36.5K

Showing 1–10 of 80

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 80 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Indiana Distribution

Michael Tallarico — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Indiana

Full comparison — all codes billed, vs. state median

80 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	4	20	11,200	$40	$631.7K
J9022	2	10	4,910	$60	$314.9K
J1449	5	10	3,300	$30	$95.5K
J0897	12	220	2,730	$20	$74.9K
J1437	4	20	2,050	$20	$60.3K
Q5122	4	10	430	$100	$46.9K
J2506	4	10	370	$80	$33.1K
J9217	79	90	150	$130	$23K
96413	5	120	140	$90	$19.1K
99214	13	10,540	110	$80	$15.5K

Showing 1–10 of 80

Related Providers

Other providers that share a Tax Identification Number (TIN) with Michael Tallarico, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Community Care Network Inc	IN	Family Medicine Physician	$0	$33.9M
St Catherine Hospital Inc	IN	General Acute Care Hospital	$0	$32.3M
Franciscan Health Crown Point	IN	General Acute Care Hospital	$0	$11.4M
Mohamad Kassar	IN	Hematology & Oncology Physician	$4.7M	$0
Ramon Lee	IL	Retina Specialist (Ophthalmology) Physician	$4M	$8.5K
Sohail Hasan	IL	Retina Specialist (Ophthalmology) Physician	$3.4M	$34.2K
Neel Shah	IN	Hematology & Oncology Physician	$3.2M	$0
Raja Devanathan	IN	Pulmonary Disease Physician	$3M	$0
Kourous Rezaei	IL	Retina Specialist (Ophthalmology) Physician	$2.7M	$0
Northwest Cancer Centers, PC	IN	Internal Medicine Physician	$0	$2.5M

Nearby Providers

Other providers in the same ZIP code as Michael Tallarico, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Franciscan Health Dyer & Hammond	IN	General Acute Care Hospital	$0	$4.5M
Tae'ni Chang-stroman M.d., P.C.	IN	Pediatrics Physician	$0	$3.5M
Cannan Healthcare Services & Staffing Inc	IN	Home Health Agency	$0	$3.2M
Pathology Consultants Inc	IN	Anatomic Pathology & Clinical Pathology Physician	$0	$2.9M
Gowri Ramadas	IN	Hematology & Oncology Physician	$1.3M	$0
Shruti Singh	IN	Hematology & Oncology Physician	$1.1M	$0
Kunwarjit Duggal	IN	Physical Medicine & Rehabilitation Physician	$669.7K	$18.8K
Donna Ward	IN	Dermatology Physician	$579.4K	$0
Laura Hoffman	IN	Dermatology Physician	$493.4K	$0
Trevor Marcotte	IN	Family Medicine Physician	$477.8K	$0

Michael Tallarico — Billing Profile & Reimbursement Data

Sign up for Michael Tallarico — Billing Profile & Reimbursement Data policy alerts

Michael Tallarico — Billing Profile & Reimbursement Data

Sign up for Michael Tallarico — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References